Literature DB >> 11181341

Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

M E Klepser1, E J Ernst, C R Petzold, P Rhomberg, G V Doern.   

Abstract

Several new quinolones that exhibit enhanced in vitro activity against Streptococcus pneumoniae have been developed. Using a dynamic in vitro model, we generated time-kill data for ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against three isolates of quinolone-susceptible S. pneumoniae. Three pharmacokinetic profiles were simulated for each of the study agents (0.1, 1, and 10 times the area under the concentration-time curve [AUC]). Target 24-h AUCs were based upon human pharmacokinetic data resulting from the maximal daily doses of each agent. Ciprofloxacin was the least active agent against all three isolates. With regimens that simulated the human 24-h AUC, ciprofloxacin resulted in an initial, modest decline in the numbers of CFU per milliliter; however, by 48 h the numbers of CFU per milliliter returned to or exceeded the starting inoculum. At the AUC, levofloxacin resulted in variable bacteriostatic and bactericidal activities against the isolates. The remaining agents yielded bactericidal (99.9% reduction) activity by 48 h with regimens that simulated the AUC. At 0.1 time the AUC ciprofloxacin and levofloxacin produced no inhibitory effect, grepafloxacin exhibited bacteriostatic activity, trovafloxacin had mixed static and cidal activities, and clinafloxacin and moxifloxacin caused significant reductions in the numbers of CFU per milliliter by 48 h. All six agents produced cidal activity at 10 times the AUC. In this dynamic in vitro model of infection, the quinolones demonstrated various degrees of activity against S. pneumoniae. The rank order of activity, with respect to bactericidal effect, was ciprofloxacin (least active) << levofloxacin < grepafloxacin, trovafloxacin < clinafloxacin and moxifloxacin (most active). The rank order of the agents with respect to the selection of resistance was ciprofloxacin (most likely) > grepafloxacin, moxifloxacin, and trovafloxacin > levofloxacin > clinafloxacin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181341      PMCID: PMC90354          DOI: 10.1128/AAC.45.3.673-678.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis.

Authors:  R C Kimbrough; W B Gerecht; F C Husted; J E Wolfe
Journal:  Mo Med       Date:  1991-09

2.  Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.

Authors:  J J Gordon; C A Kauffman
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

3.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Pneumococcal meningitis during intravenous ciprofloxacin therapy.

Authors:  J Righter
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

5.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

7.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Ciprofloxacin in acute exacerbations of chronic bronchitis.

Authors:  J A Hoogkamp-Korstanje; S J Klein
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

10.  Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.

Authors:  C Thornsberry; P T Ogilvie; H P Holley; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

View more
  12 in total

1.  Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.

Authors:  Martina Ulrich; Cordula Albers; Jan-Georg Möller; Axel Dalhoff; Gisela Korfmann; Frank Künkele; Gerd Döring
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Moxifloxacin dosing in post-bariatric surgery patients.

Authors:  Pieter Colin; Douglas J Eleveld; Michel M R F Struys; Huybrecht T'Jollyn; Luc M Van Bortel; Johannes Ruige; Jan De Waele; Jan Van Bocxlaer; Koen Boussery
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

4.  Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.

Authors:  Joseph L Campbell; Michael P Fay; Lynda L Lanning; Judith A Hewitt
Journal:  Clin Infect Dis       Date:  2020-05-21       Impact factor: 9.079

5.  Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.

Authors:  Amy Sarah Ginsburg; Jin Lee; Samuel C Woolwine; Jacques H Grosset; Fayez M Hamzeh; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 6.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Trends in antibiotic resistance in bacterial keratitis isolates from South India.

Authors:  Prajna Lalitha; Geetha Manoharan; Rajaram Karpagam; Namperumalsamy V Prajna; Muthiah Srinivasan; Jeena Mascarenhas; Manoranjan Das; Travis C Porco; Thomas M Lietman; Vicky Cevallos; Jeremy D Keenan
Journal:  Br J Ophthalmol       Date:  2016-04-29       Impact factor: 4.638

Review 8.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic.

Authors:  Hee-Jeong Yun; Yu-Hong Min; Jung-A Lim; Jin-Wook Kang; So-Young Kim; Mi-Jeong Kim; Jae-Hee Jeong; Yun-Jeong Choi; Hyun-Jin Kwon; Yong-Ho Jung; Mi-Ja Shim; Eung-Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.